Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Tony De Martini

Interventional Cardiology Springfield, IL Medical Doctor

NPI 1174604631 CMS profile 1304896

201 E Madison St, Springfield, IL 62702

Open in the dashboard

General payments

$208,459

257 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tony De Martini of Springfield, IL is reported in the CMS Open Payments database as having received $208,459 across 257 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $7,446 29
2024 General $21,121 44
2023 General $14,189 50
2022 General $41,296 54
2021 General $12,391 9
2020 General $36,434 30
2019 General $75,583 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tony De Martini
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Tony De Martini were reported at $7,446. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Tony De Martini Interventional Cardiology median Middle half National median
2019 $75,583 $1,097 $329–$3,048 $163
2020 $36,434 $473 $161–$1,480 $114
2021 $12,391 $677 $233–$1,827 $132
2022 $41,296 $978 $333–$2,724 $149
2023 $14,189 $1,136 $382–$2,986 $160
2024 $21,121 $1,181 $395–$3,326 $164
2025 $7,446 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $135,227 120 payments
  2. Asahi Intecc USA, Inc. $29,167 73 payments
  3. Siemens Medical Solutions USA, Inc. $21,156 14 payments
  4. Abbott Laboratories $13,350 7 payments
  5. Abiomed $5,407 14 payments
  6. Medtronic, Inc. $3,039 17 payments
  7. Asahi Intecc Co., Ltd. $337 2 payments
  8. Shockwave Medical, Inc $261 4 payments
  9. Ostial Corporation $167 2 payments
  10. Edwards Lifesciences Corporation $161 1 payment
  11. Other $187 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $119,724 40 payments
  2. Consulting Fee $32,450 9 payments
  3. Honoraria $30,617 11 payments
  4. Travel and Lodging $16,664 40 payments
  5. Food and Beverage $9,002 156 payments
  6. Education $2 1 payment
Products named General payments · program years 2019–2025
  1. CROSSBOSS $20,669 9 payments
  2. GENERAL - VASCULAR ACCESS Vascular $16,603 10 payments
  3. General - Vascular Access General - Vascular Access_IC $16,278 9 payments
  4. ASAHI PTCA Guide Wire $15,263 38 payments
  5. AVVIGO Guidance System $14,799 17 payments
  6. Xience V coronary stent system $13,250 3 payments
  7. STINGRAY $12,087 3 payments
  8. GENERAL VASCULAR ACCESS $11,142 6 payments
  9. Artis icono $8,585 10 payments
  10. General Therapies $6,509 5 payments
  11. Other $43,149 122 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

448

Median for Interventional Cardiology: 2,236

Drug cost

$59,737

Median for Interventional Cardiology: $380,412

Branded share of claims

34.6%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 35 $29,300
Xarelto Rivaroxaban Brand 13 $20,552
Repatha Sureclick Evolocumab Brand 12 $6,447
Clopidogrel Clopidogrel Bisulfate Brand 79 $873
Metoprolol Succinate Generic 36 $548
Atorvastatin Calcium Generic 67 $471
Carvedilol Generic 45 $344
Amlodipine Besylate Generic 35 $231
Losartan Potassium Generic 24 $226
Metoprolol Tartrate Generic 32 $226

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$12,504

Medicare's payments for the services billed

Medicare patients

41

Average age 76

Services billed

75

14 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 49%
Arthritis 49%
Diabetes 44%
Atrial fibrillation 39%
Chronic kidney disease 39%
COPD 37%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

257 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record